131 related articles for article (PubMed ID: 1203891)
21. Cellular response to treatment with 4-(3-(2-chloroethyl)-3-nitrosoureido)-cis-cyclohexanecarboxylic acid, a water-soluble nitrosourea derivative.
Drewinko B; Green C; Loo TL
Cancer Treat Rep; 1977 Nov; 61(8):1513-8. PubMed ID: 922754
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of 1,3-bis(2-chloroethyl)-1-nitrosourea resistance by gamma-irradiation or drug pretreatment in rat hepatoma cells.
Habraken Y; Laval F
Cancer Res; 1991 Feb; 51(4):1217-20. PubMed ID: 1847658
[TBL] [Abstract][Full Text] [Related]
23. Response of exponentially growing, stationary-phase, and synchronized cultured human colon carcinoma cells to treatment with nitrosourea derivatives.
Drewinko B; Barlogie B; Freireich EJ
Cancer Res; 1979 Jul; 39(7 Pt 1):2630-6. PubMed ID: 445465
[TBL] [Abstract][Full Text] [Related]
24. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro.
Melvik JE; Pettersen EO
Radiat Res; 1988 Jun; 114(3):489-99. PubMed ID: 3375438
[TBL] [Abstract][Full Text] [Related]
25. Effect of alpha-difluoromethylornithine on 1,3-bis(2-chloroethyl)-1-nitrosourea and cis-diamminedichloroplatinum(II) cytotoxicity, DNA interstrand cross-linking, and growth in human brain tumor cell lines in vitro.
Hunter KJ; Deen DF; Pellarin M; Marton LJ
Cancer Res; 1990 May; 50(9):2769-72. PubMed ID: 2109657
[TBL] [Abstract][Full Text] [Related]
26. [Antitumor action of cis-dichlorodiammineplatinum(II) and the effectiveness of a combination with sarcolysine].
Presnov MA; Konovalova AL; Romanova LF; Sof'ina ZP; Stetsenko AI
Vopr Onkol; 1978; 24(4):53-60. PubMed ID: 654174
[TBL] [Abstract][Full Text] [Related]
27. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C.
Barlogie B; Corry PM; Drewinko B
Cancer Res; 1980 Apr; 40(4):1165-8. PubMed ID: 7188883
[TBL] [Abstract][Full Text] [Related]
28. Reduction of cis-dichlorodiammineplatinum(II) caused nephrotoxicity by indazolone carboxylic acid.
Radacić M; Boranić M; Skarić D; Skarić V; Mihalić H; Gajsak V; Jercić J; Lelieveld P
Oncology; 1987; 44(1):34-7. PubMed ID: 3561926
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture.
Yung WK; Shapiro JR; Shapiro WR
Cancer Res; 1982 Mar; 42(3):992-8. PubMed ID: 7199383
[TBL] [Abstract][Full Text] [Related]
30. Effect of cis- and trans-dichlorodiammineplatinum(II) on human tumor cell proliferation in diffusion chambers in vivo.
Ambrose KR; Lowrey JS
Cancer Res; 1982 May; 42(5):1769-73. PubMed ID: 7039818
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of cis-dichlorodiammineplatinum(II) in advanced malignant lymphoma and small cell lung cancer: preliminary results.
Cavalli F; Jungi WF; Sonntag RW; Nissen NI; Holland JF
Cancer Treat Rep; 1979; 63(9-10):1599-603. PubMed ID: 227599
[TBL] [Abstract][Full Text] [Related]
32. cis-dichlorodiammineplatinum(II) chemotherapy in experimental murine myeloma MOPC 104E.
Ghanta VK; Jones MT; Woodard DA; Durant JR; Hiramoto RN
Cancer Res; 1977 Mar; 37(3):771-4. PubMed ID: 851480
[TBL] [Abstract][Full Text] [Related]
33. Protein accumulation in lethally damaged cells after treatment with cis-dichlorodiammineplatinum (II): lack of temporal correlation between drug effect and inhibition of spheroid volume growth.
Nordal AK; Juul NO; Pettersen EO
Anticancer Res; 1992; 12(2):305-11. PubMed ID: 1580548
[TBL] [Abstract][Full Text] [Related]
34. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study.
Rossof AH; Coltman CA; Jones SE; Talley RW
Cancer Treat Rep; 1979; 63(9-10):1605-8. PubMed ID: 498159
[TBL] [Abstract][Full Text] [Related]
35. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.
Aida T; Bodell WJ
Cancer Res; 1987 Mar; 47(5):1361-6. PubMed ID: 3469016
[TBL] [Abstract][Full Text] [Related]
36. Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo.
Wang YF; Curtis JE; Lipton J; Minkin S; McCulloch EA
Leukemia; 1991 Jun; 5(6):522-7. PubMed ID: 1711641
[TBL] [Abstract][Full Text] [Related]
37. Toxic variability and radiation sensitization by dichlorodiammineplatinum(II) complexes in Salmonella typhimurium cells.
Richmond RC
Radiat Res; 1984 Sep; 99(3):596-608. PubMed ID: 6382408
[TBL] [Abstract][Full Text] [Related]
38. Cytostatic activity in vitro of new cis-dichlorodiammineplatinum (II) analogs.
Duś D; Kuduk-Jaworska J
Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):357-61. PubMed ID: 6892202
[TBL] [Abstract][Full Text] [Related]
39. Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs.
Prestayko AW; Bradner WT; Huftalen JB; Rose WC; Schurig JE; Cleare MJ; Hydes PC; Crooke ST
Cancer Treat Rep; 1979; 63(9-10):1503-8. PubMed ID: 498150
[TBL] [Abstract][Full Text] [Related]
40. Survival and cycle-progression delay of cultured human lymphoma cells treated with 1-propanol, 3,3'-iminodi-, dimethanesulfonate (ester), hydrochloride (Yoshi 864).
Drewinko B; Barlogie B
Cancer Treat Rep; 1976 Nov; 60(11):1637-45. PubMed ID: 191191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
